Elotuzumab Clinical Trials
10 recruitingDrug
Phase 15Phase 25Phase 34
Showing 1–10 of 10 trials
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled274 locationsNCT06152575
Recruiting
Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Multiple Myeloma
Janssen Research & Development, LLC795 enrolled242 locationsNCT06208150
Recruiting
Phase 3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
AbbVie380 enrolled166 locationsNCT06158841
Recruiting
Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals410 enrolled159 locationsNCT05730036
Recruiting
Phase 1
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Abdullah Khan27 enrolled1 locationNCT05981209
Recruiting
Phase 1Phase 2
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Multiple Myeloma
Karyopharm Therapeutics Inc300 enrolled25 locationsNCT02343042
Recruiting
Phase 1Phase 2
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Multiple MyelomaMyelomaRefractory Multiple Myeloma
Omar Nadeem, MD49 enrolled3 locationsNCT06518551
Recruiting
Phase 1Phase 2
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Multiple Myeloma
Yale University24 enrolled1 locationNCT05002816
Recruiting
Phase 1Phase 2
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Recurrent Multiple Myeloma
Mayo Clinic37 enrolled1 locationNCT06785415
Recruiting
Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
Medical College of Wisconsin53 enrolled2 locationsNCT04835129